Featured

Helpers don’t clock out: CD4s essential for both priming and effector phases of ICB

While CD4+ T cells are crucial for CD8+ T cell priming in ICB-induced antitumor responses, their helper role at the effector phase remains largely unknown. Ameh et al. used murine MHC-II- sarcoma models to study CD4+ T cell help during ICB treatment...

Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma

Karapetyan et al. profiled TIL infusion products and matched TIMEs from patients with metastatic melanoma treated on TIL-based trials with or without ICB or BRAFi, and found that responders had infusi...

Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models

Rouanne et al. engineered probiotic E.coli (EcN) using a synchronized lysis integrated circuit to release human CXCL13 at critical population densities, without impeding normal bacterial growth. EcN C...

Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models

Inspired by clinical data that the neuropeptide vasoactive intestinal peptide (VIP), acting through its receptor (VIPR), was correlated with poor response in patients undergoing CAR therapy, Lin et al...

Single-nucleus multimodal spatial transcriptomics reveals spatial colocalization of neoantigen-expressing tumor cells and cognate T cells

Nagler, Sud, and Ghannam et al. developed a droplet-based single-nucleus spatial transcriptomics platform, Slide-GoTags, that integrates genotyping, TCR sequencing, and snRNAseq from the same frozen s...

See all for this week

Previous Digests

cDC1s serve as architects for the formation and maintenance of tumoral TLSs

July 29, 2026

The presence of tertiary lymphoid structures (TLSs) in tumors is associated with improved outcomes and response to immune checkpoint blockade (ICB). Although the cell populations within these TLSs are well established, the precise contributions of DCs to TLS formation...

CARM1 inactivation in cDC1s completes the antitumor trifecta

July 22, 2026

Coactivator-associated arginine methyltransferase (CARM1) is an epigenetic enzyme that controls transcription by methylating arginine residues of chromatin-associated proteins. In previous research, deletion or inhibition of CARM1 in tumor cells enhanced their IFNγ production and sensitized them to T cell-mediated...

Turning up the heat: iSBRT and immunotherapy induce immune reprogramming in cold breast tumors in the clinic

July 15, 2026

The tumor immune microenvironment (TIME) of ER+HER2- high-risk early breast cancer is generally immune-cold, which limits immune checkpoint blockade (ICB) responses. Since radiotherapy may modulate the immune response, it may increase ICB efficacy. However, radiotherapy may also activate the...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials